Amgen Inc

US

AMGN

Health Care

271.91 ₽

Current price

Hold
271.91 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    354 / 1361

  • Position in country

    6223 / 14179

  • Return on Assets, %

    7.9

    -40.3

  • Net income margin, %

    9.3

    -180

  • EBITDA margin, %

    32.5

    -168.2

  • Debt to Equity, %

    1036.7

    3.2

  • Intangible assets and goodwill, %

    52.7

    0.2

  • Revenue CAGR 3Y, %

    3.5

    12.5

  • Total Equity change 1Y, %

    70.2

    -9

  • Revenue Y, % chg

    7

    0

  • P/E

    21.3

    31

  • P/BV

    22.9

    1.8

  • P/S

    5

    10.3

  • EV/S

    6.9

    7.5

  • EV/EBITDA

    16

    -1.6

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    19.7

    131.1

  • Forward P/E

    13.3

    21.4

  • Dividend Yield, %

    3.3

    1.1

  • Forward Dividend Yield, %

    3.5

    0.1

  • Expected dividend per share

    9.4

    0

  • Payout Ratio, %

    69.1

    0

  • Dividend Ex Date

    2024-05-16

Get an analytical review of this company

Competitors

Ranks

  • Vertex Pharmaceuticals Inc

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Biomarin Pharmaceutical Inc

    00%

  • Seagen Inc

    00%

  • Amgen Inc

    00%

  • Moderna Inc

    00%

  • Alnylam Pharmaceuticals Inc

    00%

  • AbbVie Inc

    00%

  • Biogen Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    143240.4

  • Ticker

    AMGN.O

  • ISIN

    US0311621009

  • IPO date

    1983-06-17

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-14

  • Date fact. publication of reports

    2023-12-31

Company Description

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.